Abstract 1682P
Background
Prostate cancer (PC) presents a significant health challenge in Africa, especially in regions like Nigeria with limited access to care. Despite medical advancements, PC treatment affects patients beyond their physical health, impacting their quality of life (QoL) and financial toxicity (FT) due to high treatment costs and inadequate insurance coverage. Patient-reported outcomes are often overlooked in African PC research, creating knowledge gaps that need to be addressed.
Methods
This descriptive cross-sectional study aimed to assess patient-reported outcomes among male PC patients at Lagos University Teaching Hospital (LUTH) and the NSIA-LUTH Cancer Centre (NLCC). Data collection involved interviewer-based structured questionnaires that inculcated QoL (FACT-P), psychosocial distress (PHQ-4), and FT (FACIT-COST). Analysis was done with RStudio, with a P-value set at <0.05 for statistical significance. Ethical approval was obtained.
Results
This study examined 200 prostate cancer patients at LUTH. Participants were primarily aged 61–70; most are married with tertiary education, and the majority are retired. Comorbidities, particularly hypertension (32.0%) and diabetes mellitus (22.5%), are prevalent. Notable findings include the impact of age, employment status, and comorbidities on QoL and FT. ECOG scores, cancer stage, and comorbidities significantly influence psychological distress levels. Associations between QoL, financial toxicity, and psychosocial distress underscore the complex interplay between these factors. No significant link was found between QoL and FT.
Conclusions
This study sheds light on the challenges faced by PC patients at LUTH, highlighting the complex interplay of factors. Economic challenges included limited health insurance coverage and financial strain. Early detection and intervention are crucial, given the distribution of cancer stages and the prevalence of comorbidities among patients. FT emerges as a significant issue, impacting patients' QoL and psychosocial well-being. The lack of significant associations with health insurance coverage suggests the need for comprehensive healthcare reforms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. O. Jimoh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11